This company is no longer active
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Tricida, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.00001 |
| 52 Week High | US$13.85 |
| 52 Week Low | US$0.00001 |
| Beta | 0.051 |
| 1 Month Change | -99.89% |
| 3 Month Change | -99.93% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Tricida enters $125M debt facility
Oct 19Tricida: Important Binary Event Coming Up
Sep 21Calculating The Intrinsic Value Of Tricida, Inc. (NASDAQ:TCDA)
Sep 14
Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares
Dec 14Tricida revises VALOR-CKD trial protocol, updates patent protection, shares down 14%
Dec 09Tricida's Veverimer CRL And Regulatory Updates: An Analysis
Nov 17Tricida slumps 46% on FDA feedback on veverimer proposal; launches cost-cutting initiatives
Oct 29Shareholder Returns
| TCDA.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -99.9% | -0.6% | 1.0% |
| 1Y | -100.0% | 10.6% | 21.9% |
Return vs Industry: TCDA.Q underperformed the US Pharmaceuticals industry which returned 6.4% over the past year.
Return vs Market: TCDA.Q underperformed the US Market which returned 14% over the past year.
Price Volatility
| TCDA.Q volatility | |
|---|---|
| TCDA.Q Average Weekly Movement | 43.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TCDA.Q's share price has been volatile over the past 3 months.
Volatility Over Time: TCDA.Q's weekly volatility has increased from 31% to 44% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 57 | Gerrit Klaerner | www.tricida.com |
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Tricida, Inc. Fundamentals Summary
| TCDA.Q fundamental statistics | |
|---|---|
| Market cap | US$580.00 |
| Earnings (TTM) | -US$133.91m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs TCDA.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCDA.Q income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$133.91m |
| Earnings | -US$133.91m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -143.5% |
How did TCDA.Q perform over the long term?
See historical performance and comparison